Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
45 Results for "
SARS-CoV PLpro
" in MedChemExpress (MCE) Product Catalog:
Products (45)
45 Results for "SARS-CoV PLpro" in MCE Product Catalog:
14
14 Publications Verification
Target:
Research Areas:
GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome .
7
7 Cited Publications
Synonyms: Acriflavinium chloride 3,6-Acridinediamine mix
7
7 Cited Publications
Cat. No.: HY-W088075
CAS No.: 69235-50-3
Synonyms: Acriflavinium chloride hydrochloride
Acriflavine (Acriflavinium chloride) hydrochloride is a fluorescent acridine dye that can be used to label nucleic acid. Acriflavine hydrochloride is an antiseptic agent. Acriflavine hydrochloride is a potent HIF-1 inhibitor that prevents the dimerization of HIF-1α and HIF-1β subunits. Acriflavine hydrochloride inhibits the interaction between monocarboxylate transporter 4 (MCT4) and Basigin. Acriflavine hydrochloride is used in cancer research, such as breast cancer, brain tumor and chronic myeloid leukemia. Acriflavine hydrochloride is a potent papain-like protease (PLpro) inhibitor, which inhibits SARS-CoV-2 .
5
5 Cited Publications
Cat. No.: HY-17542
CAS No.: 1093070-14-4
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM . PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM .
4
4 Cited Publications
Cat. No.: HY-N1910
CAS No.: 20784-60-5
3
Category:
Quinones Liliaceae Anthraquinones Other Diseases Aloe vera (L.) Burm. f. Phenols Polyphenols Plants Disease Research Fields
Target:
1
Cat. No.: HY-169092
CAS No.: 3041047-51-9
Target:
Research Areas:
PF-07957472 (Compound 4) is an orally active and selective SARS-CoV-2 papain-like protease (PLpro) inhibitor, with a Ki of 2 nM against SARS-CoV-2 PLpro. PF-07957472 reduces SARS-CoV-2 viral titers in the lungs of infected mice and inhibits SARS-CoV-2-induced cytopathic effects in cells. PF-07957472 can be used for the research of COVID-19 .
Cat. No.: HY-P4388
CAS No.: 167698-69-3
Cat. No.: HY-178160
CAS No.: 1581755-42-1
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-2 (Compound 12) is a highly selective SARS-CoV-2 papain-like protease (PLpro) inhibitor of (IC50=0.06 μM). SARS-CoV-2 PLpro-IN-2 inhibits viral replication and immune evasion. SARS-CoV-2 PLpro-IN-2 exhibits antiviral efficacy in HeLa-ACE2 cells (EC50=2.9 μM). SARS-CoV-2 PLpro-IN-2 is promising for research of COVID-19 .
Cat. No.: HY-159633
CAS No.: 3009839-42-0
PLpro-IN-5 (compound 21) is a PLPro protease inhibitor with an IC50 value of 91.14 nM. PLpro-IN-5 shows broad-spectrum antivirus, especially for SARS-CoV, MERS-CoV, SARS-CoV-2 .
Cat. No.: HY-168259
PLpro-IN-8 (compound 1) is a SARS-CoV papain-like protease (PLpro) inhibitor with IC50 values of 5.9 μM and 0.46 μM for SARS-CoV-2 PLpro and SARS -CoV-1 PLpro, respectively. PLpro-IN-8 inhibits Wuhan strain WK-521 of SARS-CoV-2 with an EC50 of 2.7 μM .
Cat. No.: HY-161729
CAS No.: 3047093-72-8
PLpro-IN-3 (compound 26R) is a potent Papain-like protease (PLpro) inhibitor with a IC50 of 1.0μM. PLpro-IN-3 exhibits antiviral activity against SARS-CoV-2 with a EC50 of 4.3 μM .
Cat. No.: HY-172350
Research Areas:
WEHI-P8 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 12 nM and a Kd of 9.0 nM. WEHI-P8 reduces viral load, body weight loss, pulmonary inflammation, immune cell infiltration and pro-inflammatory mediator levels in SARS-CoV-2-infected mice. WEHI-P8 prevents pulmonary hemorrhage, immune cell infiltration, fibrotic remodeling and neuroinflammation, and improves cognitive function in a mouse model of post-acute sequelae of SARS-CoV-2 infection (PASC). WEHI-P8 is applicable for the research of COVID-19 and PASC .
Cat. No.: HY-179293
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations .
Cat. No.: HY-181927
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-7 (Compound 18) is a selective SARS-CoV-2 PLpro inhibitor with an IC50 of 13.3 μM. SARS-CoV-2 PLpro-IN-7 exerts antiviral activity against SARS-CoV-2 (with an EC50 of 11 μM for SARS-CoV-2 in Huh7.5 cells). SARS-CoV-2 PLpro-IN-7 is applicable to research related to COVID-19 .
Cat. No.: HY-181262
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-4 is a SARS-CoV-2 papain-like protease (PL Pro) inhibitor with an IC50 of 0.4 μM. SARS-CoV-2 PLpro-IN-4 binds to the S3 and S4 pockets of SARS-CoV-2 PL Pro, thereby functionally inhibiting its activity. SARS-CoV-2 PLpro-IN-4 exhibits antiviral activity and can be used in research on COVID-19 .
Cat. No.: HY-170399
CAS No.: 3053753-61-7
Target:
SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM .
Cat. No.: HY-181641
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-6 is an irreversible SARS-CoV-2 papain-like protease inhibitor with an IC50 value of 0.059 μM. SARS-CoV-2 PLpro-IN-6 exhibits antiviral activity and can be used in studies related to COVID-19 .
Cat. No.: HY-157144
CAS No.: 2682897-84-1
SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
